|
|
2207 Bridgepointe Parkway, Suite 250
San Mateo, CA 94404 USA
phone:(650) 588-6404
fax:(650) 588-2787
|
|
| Symbol |
TLON |
| Exchange |
OTC-BB |
| Founded |
0 |
| Employees |
|
|
|
| www.talontx.com.
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
|
|
| Management |
| Steven R. Deitcher , MD, President & Chief Executive Officer; Anne E. Hagey , MD, Vice President and Chief Medical Officer; Gradon D. Knotts Vice President, Business Development; Tyler M. Nielsen, Interim Vice President, Chief Financial Officer; Christopher Salentine , PhD, Vice President, Chemistry and Manufacturing |
| |
|
|
|
|
|
|
|
| Keywords |
| marqibo, alocrest, brakiva, menadione, topical lotion, hana biosciences |
|
|
|
| Description |
|
Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees. |
|
| Products / Services |
Marqibo® (vincristine sulfate liposomes injection, OPTISOME?)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin?s lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma.
More Details »
Alocrest? (vinorelbine liposomes injection, OPTISOME?)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest? has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »
Brakiva? (topotecan liposomes injection, OPTISOME?)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva? over conventional topotecan. More Details »
Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor.
More Details »
|
|
| Technology / Differentiation |
| PT-523 is a novel non-classical antifolate that is a water-soluble, nonpolyglutamatable analogue of aminopterin. PT-523 exhibits 10-fold higher affinity to its target enzyme DHFR (dihydrofolate reductase) than MTX (methotrexate) and utilizes the membrane-bound transporter (RFC) 10-fold more efficiently than MTX.
IPdR is a novel oral prodrug of IUdR being developed as a radiation therapy sensitizer for the treatment of brain cancers. IPdR is converted to IUdR by a hepatic aldehyde oxidase.
Ondansetron Lingual Spray (OLS) is a novel delivery system that utilizes the vast and highly absorptive surfaces of the oral mucosa to deliver ondansetron directly into the bloodstream, thus achieving therapeutic levels in a shorter period of time than conventional oral dosage forms. Ondansetron is a selective blocking agent of the seratonin 5-HT3 receptor and is widely accepted as the standard of care to prevent chemotherapy-induced nausea and vomiting. Ondansetron LS may provide a more rapid delivery of ondansetron to prevent nausea and vomiting as compared to current oral forms by avoiding the "first-pass effect" -- since drug delivery via the oral mucosa avoids degradation in the gastrointestinal tract and metabolism by liver enzymes. |
|
| Market / Customers |
Cancer is the second leading cause of death in the United States. This year, one in four deaths in the US is expected to be due to cancer and 1.4 million new cases will be diagnosed. For all forms of cancer combined, the 5-year relative survival rate is 64%. Despite the fact that the cancer mortality rate in the U.S. has risen steadily for the past 50 years, scientific advances appear to have begun to turn the tide. 1997 was the first year in the past half century in which fewer Americans died of cancer than the year before - the start of what researchers hope will be a long-term decline in cancer deaths.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
